Artificial Diuresis: Animal Studies on Efficacy and Safety of a New Miniaturized Device for Extracorporeal Ultrafiltration.

IF 2.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiorenal Medicine Pub Date : 2023-01-01 Epub Date: 2023-03-28 DOI:10.1159/000530382
Anna Lorenzin, Luca Sgarabotto, Maria Laura Bacci, Alberto Elmi, Domenico Ventrella, Camilla Aniballi, Monica Zanella, Alessandra Brendolan, Luca Di Lullo, Claudio Ronco
{"title":"Artificial Diuresis: Animal Studies on Efficacy and Safety of a New Miniaturized Device for Extracorporeal Ultrafiltration.","authors":"Anna Lorenzin, Luca Sgarabotto, Maria Laura Bacci, Alberto Elmi, Domenico Ventrella, Camilla Aniballi, Monica Zanella, Alessandra Brendolan, Luca Di Lullo, Claudio Ronco","doi":"10.1159/000530382","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We have recently developed a new miniaturized device for extracorporeal ultrafiltration (UF) to be used in patients with fluid overload: Artificial Diuresis-1 (AD1) (Medica S.p.A., Medolla, Italy). The device has a reduced priming volume, operates at very low pressures and flow regimes, and is designed to perform extracorporeal UF at bedside. After accurate experiments were carried out in vitro, we report in this paper the results of in vivo UF sessions carried out in selected animals according to veterinary best practice.</p><p><strong>Materials and methods: </strong>The AD1 kit is pre-filled with sterile isotonic solution and operates with a polysulfone mini-filter, MediSulfone (polysulfone at 50,000 Dalton). A collection bag with a volumetric scale is connected to the UF line, and the ultrafiltrate is obtained by gravity based on the height at which the ultrafiltrate collection bag is placed. Animals were prepared and anesthetized. The jugular vein was cannulated with a double-lumen catheter. Three 6-h sessions of UF were scheduled with a target fluid removal of 1,500 mL. Heparin was used as anticoagulant.</p><p><strong>Results: </strong>In all treatments, the target value of UF was obtained in the absence of major clinical or technical problems with a maximum deviation from the scheduled UF rate lower than 10%. The device resulted to be safe, reliable, accurate, and easily usable thanks to a user-friendly interface and its very small dimensions.</p><p><strong>Conclusions: </strong>This study opens the way for clinical trials in different settings including departments with low intensity of care and even in ambulatory centers or patient's home.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"167-175"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000530382","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: We have recently developed a new miniaturized device for extracorporeal ultrafiltration (UF) to be used in patients with fluid overload: Artificial Diuresis-1 (AD1) (Medica S.p.A., Medolla, Italy). The device has a reduced priming volume, operates at very low pressures and flow regimes, and is designed to perform extracorporeal UF at bedside. After accurate experiments were carried out in vitro, we report in this paper the results of in vivo UF sessions carried out in selected animals according to veterinary best practice.

Materials and methods: The AD1 kit is pre-filled with sterile isotonic solution and operates with a polysulfone mini-filter, MediSulfone (polysulfone at 50,000 Dalton). A collection bag with a volumetric scale is connected to the UF line, and the ultrafiltrate is obtained by gravity based on the height at which the ultrafiltrate collection bag is placed. Animals were prepared and anesthetized. The jugular vein was cannulated with a double-lumen catheter. Three 6-h sessions of UF were scheduled with a target fluid removal of 1,500 mL. Heparin was used as anticoagulant.

Results: In all treatments, the target value of UF was obtained in the absence of major clinical or technical problems with a maximum deviation from the scheduled UF rate lower than 10%. The device resulted to be safe, reliable, accurate, and easily usable thanks to a user-friendly interface and its very small dimensions.

Conclusions: This study opens the way for clinical trials in different settings including departments with low intensity of care and even in ambulatory centers or patient's home.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
人工利尿:新型微型体外超滤装置的有效性和安全性动物研究。
简介:我们最近开发了一种新型体外超滤(UF)微型装置,可用于体液超负荷患者:Artificial Diuresis-1 (AD1) (Medica S.p.A., Medolla, Italy)。该设备具有较小的启动体积,可在极低的压力和流量下运行,设计用于在床边进行体外超滤。在进行了精确的体外实验后,我们在本文中报告了根据兽医最佳实践在选定动物体内进行体外超滤的结果:AD1 套件预装了无菌等渗溶液,并配有聚砜微型过滤器 MediSulfone(聚砜,50,000 道尔顿)。带有体积刻度的收集袋与超滤管路相连,根据超滤液收集袋放置的高度,通过重力获得超滤液。对动物进行准备和麻醉。用双腔导管插入颈静脉。计划进行三次为期 6 小时的超滤,目标是排出 1,500 毫升液体。肝素被用作抗凝剂:结果:在所有治疗过程中,超滤量都达到了目标值,没有出现重大临床或技术问题,与计划超滤量的最大偏差低于 10%。该设备安全、可靠、准确、易于使用,这得益于其友好的用户界面和非常小的尺寸:这项研究为在不同环境下进行临床试验开辟了道路,包括护理强度较低的科室,甚至门诊中心或患者家中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiorenal Medicine
Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY
CiteScore
5.40
自引率
2.60%
发文量
25
审稿时长
>12 weeks
期刊介绍: The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.
期刊最新文献
A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units. Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data. EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure. Cardiorenal disease and heart failure with preserved ejection fraction: Two sides of the same coin. Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin Following an Admission for Acute Heart Failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1